Osteoporosis:

Osteoporosis is the thinning of bone
tissue and loss of bone density over
time.



PROLIA APPROVED FOR
OSTEOPOROSIS, TESTED FOR
CANCER
Prolia (denosumab)  was approved in
all 27 European Union member states
and in the US  for use in
postmenopausal women at risk of
fractures and for bone loss due to
hormone ablation treatment in men
with prostate cancer.
An inexpensive twice yearly shot, made
by Amgen.
Successful trials of the drug  in women
show it dramatically cuts the number of
spine and hip fractures, and helps
bones to regrow.
A large number of women  are unable
to take bisphosphonates and risk their
bones deteriorating further without
treatment.
If Amgen can prove that Prolia can
help prevent bone problems for cancer
patients analysts will give Prolia a solid
shot at megablockbuster sales of $3
billion a year.
Prolia  will cost $825 per 60-mg
injection - or $1,650 for the
recommended twice-yearly injections. It
marks about a 50 percent premium to
injectable bisphosphonate Reclast
(zoledronic acid, Novartis AG) and a
25 percent to 35 percent premium to
oral bisphosphonates such as Boniva
(ibandronate, Roche AG and
GlaxoSmithKline plc) and Actonel
(risedronate, Proctor & Gamble
Pharmaceuticals and Sanofi-Aventis
Group).
But given Prolia's impressive data,
including results from a head-to-head
study in which the RANK ligand
inhibitor bested oral bisphosphonate
Fosamax (alendronate, Merck & Co.
Inc.) in improving bone mineral density,
that higher pricing is not likely to be a
deterrent.



OTHER DEVELOPMENTS
Pfizer's  Fablyn, if approved,  enters a
market already crowded with other
drugs including  Novartis's  Reclast,
Roche Holding's  Boniva, Procter &
Gamble Co's Actonel and Merck & Co
Inc's Fosamax.

Forteo by Eli Lilly;